Style | Citing Format |
---|---|
MLA | Ranjbar S, et al.. "Probiotics for Prophylaxis and Management of Breast Cancer: Preclinical and Clinical Evidence." Probiotic Research in Therapeutics: Volume 1: Applications in Cancers and Immunological Diseases, vol. 1, no. , 2020, pp. 159-189. |
APA | Ranjbar S, Seyednejad SA, Zakeri SE, Rezaeizadeh H, Rahimi R (2020). Probiotics for Prophylaxis and Management of Breast Cancer: Preclinical and Clinical Evidence. Probiotic Research in Therapeutics: Volume 1: Applications in Cancers and Immunological Diseases, 1(), 159-189. |
Chicago | Ranjbar S, Seyednejad SA, Zakeri SE, Rezaeizadeh H, Rahimi R. "Probiotics for Prophylaxis and Management of Breast Cancer: Preclinical and Clinical Evidence." Probiotic Research in Therapeutics: Volume 1: Applications in Cancers and Immunological Diseases 1, no. (2020): 159-189. |
Harvard | Ranjbar S et al. (2020) 'Probiotics for Prophylaxis and Management of Breast Cancer: Preclinical and Clinical Evidence', Probiotic Research in Therapeutics: Volume 1: Applications in Cancers and Immunological Diseases, 1(), pp. 159-189. |
Vancouver | Ranjbar S, Seyednejad SA, Zakeri SE, Rezaeizadeh H, Rahimi R. Probiotics for Prophylaxis and Management of Breast Cancer: Preclinical and Clinical Evidence. Probiotic Research in Therapeutics: Volume 1: Applications in Cancers and Immunological Diseases. 2020;1():159-189. |
BibTex | @article{ author = {Ranjbar S and Seyednejad SA and Zakeri SE and Rezaeizadeh H and Rahimi R}, title = {Probiotics for Prophylaxis and Management of Breast Cancer: Preclinical and Clinical Evidence}, journal = {Probiotic Research in Therapeutics: Volume 1: Applications in Cancers and Immunological Diseases}, volume = {1}, number = {}, pages = {159-189}, year = {2020} } |
RIS | TY - JOUR AU - Ranjbar S AU - Seyednejad SA AU - Zakeri SE AU - Rezaeizadeh H AU - Rahimi R TI - Probiotics for Prophylaxis and Management of Breast Cancer: Preclinical and Clinical Evidence JO - Probiotic Research in Therapeutics: Volume 1: Applications in Cancers and Immunological Diseases VL - 1 IS - SP - 159 EP - 189 PY - 2020 ER - |